Adcetris for Hodgkin Lymphoma - Details


( Last Updated : September 17, 2013)
Generic Name:
Brentuximab vedotin
Project Status:
Complete
Therapeutic Area:
Hodgkin Lymphoma
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0020-000
NOC Date:

Details


Strength:
50 mg/vial
Tumour Type:
Lymphoma
Indications:
Hodgkin Lymphoma
Funding Request:
For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.